Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ICLUSIG® (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. This landmark approval makes ICLUSIG the first and only targeted therapy in the U.S. for frontline Ph+ ALL, distinguishing itself by its utilization of minimal residual disease (MRD)-negative complete remission (CR) as a novel primary endpoint for approval.
The FDA’s accelerated approval is based on the results from the Phase 3 PhALLCON Trial, where ICLUSIG demonstrated superior MRD-negative CR rates compared to imatinib, a previously available treatment, alongside a comparable safety profile. MRD-negative CR, a crucial prognostic indicator, reflects both molecular and clinical responses which are key for long-term patient outcomes.
This approval, granted Priority Review and evaluated under the Real-Time Oncology Review (RTOR) program, symbolizes a significant step forward in the treatment of Ph+ ALL, a rare and aggressive cancer. Takeda’s commitment to addressing unmet needs in cancer care is evident in this development, offering a new hope for enhanced patient outcomes. Further confirmation of ICLUSIG’s clinical benefits is expected through confirmatory trials, as required for continued FDA approval under the accelerated approval pathway.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
